Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder each batch is verified to ≥98% purity by RP-HPLC and mass spectrometry.
Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.
For research use only. Not for human consumption.
Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder each batch is verified to ≥98% purity by RP-HPLC and mass spectrometry.
Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.
For research use only. Not for human consumption.